Literature DB >> 19874995

High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy.

Mackram F Eleid1, Tomas Konecny, Marek Orban, Partho P Sengupta, Virend K Somers, James M Parish, Farouk Mookadam, Peter A Brady, Barbara L Sullivan, Bijoy K Khandheria, Steve R Ommen, A Jamil Tajik.   

Abstract

OBJECTIVES: We sought to determine the prevalence of nocturnal oxygen desaturation and obstructive sleep apnea (OSA) in a population of patients with hypertrophic cardiomyopathy (HCM).
BACKGROUND: The coexistence of sleep apnea and HCM, 2 common cardiovascular conditions, has been largely unrecognized in the treatment of patients with HCM. The nocturnal hypoxia-induced hyperadrenergic state in OSA is expected to worsen hemodynamics and outcomes in HCM.
METHODS: One hundred subjects with HCM between June 1, 2006, and July 14, 2008, were screened with nocturnal oximetry. Clinical variables were collected for statistical analysis. Oximetry was classified abnormal (suspicion of sleep-disordered breathing) in the presence of repetitive desaturation (> or =5 events/h) followed by a rapid return to baseline oxygen saturation (SaO(2)) level with a decrease of > or =4% and threshold of 90%.
RESULTS: Seventy-one (71%) patients with HCM had abnormal nocturnal oximetry (71 +/- 9%, 95% confidence interval: 62% to 80%). Subjects with abnormal oximetry were older (age 59.5 +/- 15.3 years) and more were hypertensive (n = 39 [55%]) than those with normal oximetry (age 45.8 +/- 18.5 years, n = 9 [31%], p < 0.001, p = 0.03). Patients with HCM were more symptomatic in the presence of abnormal oximetry (New York Heart Association functional class II to III) (62% vs. 83%, p = 0.023). HCM patients had a higher prevalence of abnormal nocturnal oximetry (n = 71, 71%) compared with a control group of similar age and sex distribution (n = 49, 49%) (p = 0.001).
CONCLUSIONS: Abnormal nocturnal oximetry is common in patients with HCM, suggesting that OSA is prevalent. OSA may impact hemodynamics and symptoms in HCM. Further studies are needed to determine the long-term benefit of OSA treatment on hemodynamics and disease progression in HCM.

Entities:  

Mesh:

Year:  2009        PMID: 19874995     DOI: 10.1016/j.jacc.2009.07.030

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

1.  Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy.

Authors:  Tomas Konecny; Jeffrey B Geske; Ondrej Ludka; Marek Orban; Peter A Brady; Muaz M Abudiab; Felipe N Albuquerque; Alexander Placek; Tomas Kara; Karine R Sahakyan; Bernard J Gersh; A Jamil Tajik; Thomas G Allison; Steve R Ommen; Virend K Somers
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

2.  Frequent periodic leg movement during sleep is associated with left ventricular hypertrophy and adverse cardiovascular outcomes.

Authors:  Mahek Mirza; Win-Kuang Shen; Aamir Sofi; Ahad Jahangir; Naoyo Mori; A Jamil Tajik; Arshad Jahangir
Journal:  J Am Soc Echocardiogr       Date:  2013-04-24       Impact factor: 5.251

Review 3.  Sleep-disordered breathing in hypertrophic cardiomyopathy: challenges and opportunities.

Authors:  Tomas Konecny; Virend K Somers
Journal:  Chest       Date:  2014-07       Impact factor: 9.410

4.  Ameliorating the severity of sleep-disordered breathing concomitant with heart failure status after percutaneous transluminal septal myocardial ablation for drug-refractory hypertrophic obstructive cardiomyopathy.

Authors:  Keitaro Akita; Yuichiro Maekawa; Takashi Kohno; Hikaru Tsuruta; Mitsushige Murata; Keiichi Fukuda
Journal:  Heart Vessels       Date:  2017-05-29       Impact factor: 2.037

Review 5.  Role of obstructive sleep apnea in cardiovascular disease.

Authors:  Ken Monahan; Susan Redline
Journal:  Curr Opin Cardiol       Date:  2011-11       Impact factor: 2.161

6.  Association of Preoperative Sleep-Disordered Breathing With Functional Status After Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy.

Authors:  Daokun Sun; Hartzell V Schaff; Virend K Somers; Rick A Nishimura; Jeffrey B Geske; Joseph A Dearani; Steve R Ommen
Journal:  CJC Open       Date:  2022-07-11

7.  Prevalence, Severity, and Prognostic Value of Sleep Apnea Syndromes in Cardiac Amyloidosis.

Authors:  Diane Bodez; Aziz Guellich; Mounira Kharoubi; Ala Covali-Noroc; Claire-Marie Tissot; Soulef Guendouz; Luc Hittinger; Jean-Luc Dubois-Randé; Jean-Pascal Lefaucheur; Violaine Planté-Bordeneuve; Serge Adnot; Laurent Boyer; Thibaud Damy
Journal:  Sleep       Date:  2016-07-01       Impact factor: 5.849

8.  The hemodynamic impact of acute nasal continuous positive airway pressure treatment in hypertrophic cardiomyopathy: is it safe?

Authors:  Bo Xu; Reena Mehra
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 3.005

Review 9.  Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy.

Authors:  Gherardo Finocchiaro; Emma Magavern; Gianfranco Sinagra; Euan Ashley; Michael Papadakis; Maite Tome-Esteban; Sanjay Sharma; Iacopo Olivotto
Journal:  J Am Heart Assoc       Date:  2017-12-13       Impact factor: 5.501

10.  Lack of reliable clinical predictors to identify obstructive sleep apnea in patients with hypertrophic cardiomyopathy.

Authors:  Flávia B Nerbass; Rodrigo P Pedrosa; Pedro R Genta; Murillo O Antunes; Edmundo Arteaga-Fernández; Luciano F Drager; Geraldo Lorenzi-Filho
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.